Cargando…

Health-Related Quality of Life Evaluation Using the Short Form-36 in Patients With Human T-Lymphotropic Virus Type 1-Associated Myelopathy

BACKGROUND: Human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy (HAM) is a neuroinflammatory disease, causing various neurological symptoms, including motor, sensory, and bladder and bowel dysfunctions. This study was designed to reveal the impact of HAM and related symptoms on health-r...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimura, Miyuna, Yamauchi, Junji, Sato, Tomoo, Yagishita, Naoko, Araya, Natsumi, Aratani, Satoko, Tanabe, Kenichiro, Horibe, Erika, Watanabe, Toshiki, Coler-Reilly, Ariella, Nagasaka, Misako, Akasu, Yukari, Kaburagi, Kei, Kikuchi, Takayuki, Shibata, Soichiro, Matsumoto, Hirofumi, Koseki, Akihito, Inoue, Soichiro, Takata, Ayako, Yamano, Yoshihisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036434/
https://www.ncbi.nlm.nih.gov/pubmed/35479934
http://dx.doi.org/10.3389/fmed.2022.879379
_version_ 1784693521735745536
author Kimura, Miyuna
Yamauchi, Junji
Sato, Tomoo
Yagishita, Naoko
Araya, Natsumi
Aratani, Satoko
Tanabe, Kenichiro
Horibe, Erika
Watanabe, Toshiki
Coler-Reilly, Ariella
Nagasaka, Misako
Akasu, Yukari
Kaburagi, Kei
Kikuchi, Takayuki
Shibata, Soichiro
Matsumoto, Hirofumi
Koseki, Akihito
Inoue, Soichiro
Takata, Ayako
Yamano, Yoshihisa
author_facet Kimura, Miyuna
Yamauchi, Junji
Sato, Tomoo
Yagishita, Naoko
Araya, Natsumi
Aratani, Satoko
Tanabe, Kenichiro
Horibe, Erika
Watanabe, Toshiki
Coler-Reilly, Ariella
Nagasaka, Misako
Akasu, Yukari
Kaburagi, Kei
Kikuchi, Takayuki
Shibata, Soichiro
Matsumoto, Hirofumi
Koseki, Akihito
Inoue, Soichiro
Takata, Ayako
Yamano, Yoshihisa
author_sort Kimura, Miyuna
collection PubMed
description BACKGROUND: Human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy (HAM) is a neuroinflammatory disease, causing various neurological symptoms, including motor, sensory, and bladder and bowel dysfunctions. This study was designed to reveal the impact of HAM and related symptoms on health-related quality of life (HRQoL). METHODS: We analyzed the Short Form-36 (SF-36) and clinical data of 538 patients with HAM registered in the HAM-net, a nationwide patient registry for HAM in Japan. HRQoL was evaluated using the SF-6D (a health state utility value calculated from the SF-36) and eight SF-36 subscales. A general liner model was used to estimate the impact of major HAM-related symptoms, including gait dysfunction, sensory disturbance in the legs (pain and numbness), urinary dysfunction, and constipation, on the SF-6D and SF-36 subscale scores. RESULTS: The mean age and disease duration were 62.0 and 16.5 years, respectively. Of the patients, 73.2% needed walking aid; 42.7 and 67.1% had leg pain and numbness, respectively; 92.1% had urinary dysfunction; and 77.9% had constipation. The mean SF-6D score was 0.565, which was significantly lower than the national average (0.674 in the 60–69 years age group; p < 0.001), exceeding the minimal important difference (0.05–0.1). All the major symptoms were significantly associated with a decrease in the SF-6D score. The SF-36 subscale scores were significantly lower than the national standard of 50 (p ≤ 0.001), except for mental health (MH). Gait dysfunction was associated with lower scores in physical functioning (PF), limitations on role functioning because of physical health, bodily pain, general health perception (GH), vitality (VT), and social functioning; however, no association was observed between gait dysfunction and limitations on role functioning because of emotional problems and MH. Meanwhile, sensory disturbance in the legs was associated with a decrease in scores in all subscales. Urinary dysfunction was associated with worse PF, GH, VT, and MH. Constipation was associated only with PF. CONCLUSION: HRQoL of patients with HAM was worse than that of the general population and was associated with all major symptoms. Thus, patients should be comprehensively managed to achieve better HRQoL.
format Online
Article
Text
id pubmed-9036434
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90364342022-04-26 Health-Related Quality of Life Evaluation Using the Short Form-36 in Patients With Human T-Lymphotropic Virus Type 1-Associated Myelopathy Kimura, Miyuna Yamauchi, Junji Sato, Tomoo Yagishita, Naoko Araya, Natsumi Aratani, Satoko Tanabe, Kenichiro Horibe, Erika Watanabe, Toshiki Coler-Reilly, Ariella Nagasaka, Misako Akasu, Yukari Kaburagi, Kei Kikuchi, Takayuki Shibata, Soichiro Matsumoto, Hirofumi Koseki, Akihito Inoue, Soichiro Takata, Ayako Yamano, Yoshihisa Front Med (Lausanne) Medicine BACKGROUND: Human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy (HAM) is a neuroinflammatory disease, causing various neurological symptoms, including motor, sensory, and bladder and bowel dysfunctions. This study was designed to reveal the impact of HAM and related symptoms on health-related quality of life (HRQoL). METHODS: We analyzed the Short Form-36 (SF-36) and clinical data of 538 patients with HAM registered in the HAM-net, a nationwide patient registry for HAM in Japan. HRQoL was evaluated using the SF-6D (a health state utility value calculated from the SF-36) and eight SF-36 subscales. A general liner model was used to estimate the impact of major HAM-related symptoms, including gait dysfunction, sensory disturbance in the legs (pain and numbness), urinary dysfunction, and constipation, on the SF-6D and SF-36 subscale scores. RESULTS: The mean age and disease duration were 62.0 and 16.5 years, respectively. Of the patients, 73.2% needed walking aid; 42.7 and 67.1% had leg pain and numbness, respectively; 92.1% had urinary dysfunction; and 77.9% had constipation. The mean SF-6D score was 0.565, which was significantly lower than the national average (0.674 in the 60–69 years age group; p < 0.001), exceeding the minimal important difference (0.05–0.1). All the major symptoms were significantly associated with a decrease in the SF-6D score. The SF-36 subscale scores were significantly lower than the national standard of 50 (p ≤ 0.001), except for mental health (MH). Gait dysfunction was associated with lower scores in physical functioning (PF), limitations on role functioning because of physical health, bodily pain, general health perception (GH), vitality (VT), and social functioning; however, no association was observed between gait dysfunction and limitations on role functioning because of emotional problems and MH. Meanwhile, sensory disturbance in the legs was associated with a decrease in scores in all subscales. Urinary dysfunction was associated with worse PF, GH, VT, and MH. Constipation was associated only with PF. CONCLUSION: HRQoL of patients with HAM was worse than that of the general population and was associated with all major symptoms. Thus, patients should be comprehensively managed to achieve better HRQoL. Frontiers Media S.A. 2022-04-11 /pmc/articles/PMC9036434/ /pubmed/35479934 http://dx.doi.org/10.3389/fmed.2022.879379 Text en Copyright © 2022 Kimura, Yamauchi, Sato, Yagishita, Araya, Aratani, Tanabe, Horibe, Watanabe, Coler-Reilly, Nagasaka, Akasu, Kaburagi, Kikuchi, Shibata, Matsumoto, Koseki, Inoue, Takata and Yamano. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Kimura, Miyuna
Yamauchi, Junji
Sato, Tomoo
Yagishita, Naoko
Araya, Natsumi
Aratani, Satoko
Tanabe, Kenichiro
Horibe, Erika
Watanabe, Toshiki
Coler-Reilly, Ariella
Nagasaka, Misako
Akasu, Yukari
Kaburagi, Kei
Kikuchi, Takayuki
Shibata, Soichiro
Matsumoto, Hirofumi
Koseki, Akihito
Inoue, Soichiro
Takata, Ayako
Yamano, Yoshihisa
Health-Related Quality of Life Evaluation Using the Short Form-36 in Patients With Human T-Lymphotropic Virus Type 1-Associated Myelopathy
title Health-Related Quality of Life Evaluation Using the Short Form-36 in Patients With Human T-Lymphotropic Virus Type 1-Associated Myelopathy
title_full Health-Related Quality of Life Evaluation Using the Short Form-36 in Patients With Human T-Lymphotropic Virus Type 1-Associated Myelopathy
title_fullStr Health-Related Quality of Life Evaluation Using the Short Form-36 in Patients With Human T-Lymphotropic Virus Type 1-Associated Myelopathy
title_full_unstemmed Health-Related Quality of Life Evaluation Using the Short Form-36 in Patients With Human T-Lymphotropic Virus Type 1-Associated Myelopathy
title_short Health-Related Quality of Life Evaluation Using the Short Form-36 in Patients With Human T-Lymphotropic Virus Type 1-Associated Myelopathy
title_sort health-related quality of life evaluation using the short form-36 in patients with human t-lymphotropic virus type 1-associated myelopathy
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036434/
https://www.ncbi.nlm.nih.gov/pubmed/35479934
http://dx.doi.org/10.3389/fmed.2022.879379
work_keys_str_mv AT kimuramiyuna healthrelatedqualityoflifeevaluationusingtheshortform36inpatientswithhumantlymphotropicvirustype1associatedmyelopathy
AT yamauchijunji healthrelatedqualityoflifeevaluationusingtheshortform36inpatientswithhumantlymphotropicvirustype1associatedmyelopathy
AT satotomoo healthrelatedqualityoflifeevaluationusingtheshortform36inpatientswithhumantlymphotropicvirustype1associatedmyelopathy
AT yagishitanaoko healthrelatedqualityoflifeevaluationusingtheshortform36inpatientswithhumantlymphotropicvirustype1associatedmyelopathy
AT arayanatsumi healthrelatedqualityoflifeevaluationusingtheshortform36inpatientswithhumantlymphotropicvirustype1associatedmyelopathy
AT aratanisatoko healthrelatedqualityoflifeevaluationusingtheshortform36inpatientswithhumantlymphotropicvirustype1associatedmyelopathy
AT tanabekenichiro healthrelatedqualityoflifeevaluationusingtheshortform36inpatientswithhumantlymphotropicvirustype1associatedmyelopathy
AT horibeerika healthrelatedqualityoflifeevaluationusingtheshortform36inpatientswithhumantlymphotropicvirustype1associatedmyelopathy
AT watanabetoshiki healthrelatedqualityoflifeevaluationusingtheshortform36inpatientswithhumantlymphotropicvirustype1associatedmyelopathy
AT colerreillyariella healthrelatedqualityoflifeevaluationusingtheshortform36inpatientswithhumantlymphotropicvirustype1associatedmyelopathy
AT nagasakamisako healthrelatedqualityoflifeevaluationusingtheshortform36inpatientswithhumantlymphotropicvirustype1associatedmyelopathy
AT akasuyukari healthrelatedqualityoflifeevaluationusingtheshortform36inpatientswithhumantlymphotropicvirustype1associatedmyelopathy
AT kaburagikei healthrelatedqualityoflifeevaluationusingtheshortform36inpatientswithhumantlymphotropicvirustype1associatedmyelopathy
AT kikuchitakayuki healthrelatedqualityoflifeevaluationusingtheshortform36inpatientswithhumantlymphotropicvirustype1associatedmyelopathy
AT shibatasoichiro healthrelatedqualityoflifeevaluationusingtheshortform36inpatientswithhumantlymphotropicvirustype1associatedmyelopathy
AT matsumotohirofumi healthrelatedqualityoflifeevaluationusingtheshortform36inpatientswithhumantlymphotropicvirustype1associatedmyelopathy
AT kosekiakihito healthrelatedqualityoflifeevaluationusingtheshortform36inpatientswithhumantlymphotropicvirustype1associatedmyelopathy
AT inouesoichiro healthrelatedqualityoflifeevaluationusingtheshortform36inpatientswithhumantlymphotropicvirustype1associatedmyelopathy
AT takataayako healthrelatedqualityoflifeevaluationusingtheshortform36inpatientswithhumantlymphotropicvirustype1associatedmyelopathy
AT yamanoyoshihisa healthrelatedqualityoflifeevaluationusingtheshortform36inpatientswithhumantlymphotropicvirustype1associatedmyelopathy